SAN FRANCISCO and SINGAPORE, May 13, 2024 (GLOBE NEWSWIRE) -- Hummingbird
Bioscience, a precision biotherapeutics company discovering and developing
transformative biologics for hard-to-treat diseases, today announced two
presentations at the 20(th) Annual PEGS Boston summit being held from May
13-17, 2024. Data from the first presentation demonstrates the ability to direct
antibodies and antibody-drug conjugates (ADCs) to rationally selected epitopes
of interest on challenging disease-associated proteins. Data from the second
presentation show how a novel dual-payload ADC approach has the potential to
address resistance and improve the therapeutic window of ADCs.
"The data presented at PEGS show for the first time how our proprietary fourth
generation antibody-drug conjugate (ADC) platform leverages novel linker and
dual-payload technologies to overcome the resistance observed with earlier
generation single payload ADCs. Our ADC technology has the potential to treat a
large number of patients that have either intrinsic or acquired resistance to
currently approved ADCs," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific
Officer, Hummingbird Bioscience. "We will also showcase how our proprietary
Rational Antibody Discovery platform engineers immune responses in transgenic
mice models so that resulting ADCs and antibodies bind to the key epitopes on
disease-associated proteins for optimal drug properties. These data continue to
support our belief that our next-generation ADC platform can generate best-in-
class ADCs that address payload resistance, optimize tumor specificity, and
enhance payload delivery, and therefore maximize the anti-tumor potential of
ADCs."
Presentation details:
Title: Engineering Immune Responses for Epitope-Focused Antibody Discovery
Presenter: Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer
Session: Display of Biologics - Novel Platforms
Date/Time: Monday, May 13, 2024, 1:45 p.m. ET
Title: Overcoming Payload Resistance with Dual-Payload ADCs
Presenter: Ben Ayers, DPhil, Vice President, Antibody-Drug Conjugates
Session: Driving Clinical Success in Antibody Drug Conjugates - Novel payloads
and MOAs
Date/Time: Friday, May 17, 2024, 9:30 a.m. ET
About Hummingbird Bioscience's ADC Platform
The 4(th) generation ADC platform developed by Hummingbird Bioscience aims to
address the key limitations in efficacy and safety of current approved ADCs. The
ADC platform combines the company's AI-enabled Rational Antibody Discovery
Platform and proprietary linker and dual-payload technologies to unlock the
power of dual-payload approaches against the most important disease-associated
proteins. The platform engineers potentially best-in-class ADCs that address
payload resistance, optimize payload delivery and tumor specificity, and
maximize anti-tumor cytotoxic potential.
About Hummingbird Bioscience's Rational Antibody Discovery Platform
The Rational Antibody Discovery (RAD) platform is designed to address the
challenges of traditional antibody approaches. This technology enables the
company to identify critical functional regions of a target protein using
mAbPredict, a machine learning-enabled technology platform that identifies
optimal regions to target, and then drives production of antibodies against
these epitopes using mAbHits, a proprietary immuno-engineering technology that
directs the antibody response to pre-determined epitopes of interest in the
proprietary transgenic HMBD Abvantage mouse. Unlike classical approaches to
antibody discovery that have limited control over antibody binding regions, and
hence, ability to target optimal epitopes, mAbHits ensures in vivo generation
and affinity maturation of antibodies against only the optimal epitope. This
systematic and rational approach to antibody discovery opens up the potential of
discovering antibodies to specific regions of many important "hard targets" that
have not been drugged or are inadequately drugged to date. The RAD platform has
produced multiple antibodies and ADCs that effectively target disease-associated
proteins, including two antibodies that are currently in Phase I trials (HMBD-
001 and HMBD-002) and a recently out-licensed ADC (HMBD-501) that will enter the
clinic in 2024.
About Hummingbird Bioscience
Hummingbird Bioscience is a precision biotherapeutics company discovering and
developing transformative biologics for hard-to-treat diseases. To address key
challenges with current antibody-drug conjugate (ADC) therapies, Hummingbird
Bioscience is building a pipeline of next-generation ADCs using its proprietary
antibody discovery and linker/payload platforms. The company has a pipeline of
ADCs in preclinical development and other novel biologics including monoclonal
antibodies, HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) in Phase I
and a recently out-licensed ADC (HMBD-501) that will enter the clinic this year.
The Hummingbird Bioscience approach combines computational and systems biology
with wet lab drug discovery in a multi-disciplinary, collaborative environment
spanning initial discovery through clinical development. The company harnesses
this integrated approach across target identification and patient selection,
enabling the team to increase the efficiency of translating novel scientific
insights while reducing the inherent risk in drug discovery and development. At
Hummingbird Bioscience, the commitment to rigorous science, teamwork, and
intellectual integrity underpins our passion to accelerate the journey of new
drugs from concept to clinic.
For more information, please visit www.hummingbirdbioscience.com
(https://www.hummingbirdbioscience.com/), and follow Hummingbird Bioscience
on LinkedIn (https://www.linkedin.com/company/hummingbird-bioscience), X
(formerly Twitter) (https://twitter.com/hummingbirdbio), and YouTube
(https://www.youtube.com/@hummingbirdbioscience).
Contacts:
Media
Crystal Ho
c.ho@hummingbirdbio.com (mailto:c.ho@hummingbirdbio.com)
media@hummingbirdbio.com (mailto:media@hummingbirdbio.com)
+65 6979 5580
Investors
investors@hummingbirdbio.com (mailto:investors@hummingbirdbio.com)
Â